GlaxoSmithKline's Dreamm-2 Multiple Myeloma Trial Results Encouraging
(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.The study, which involved 196 patients
Read more